Company Analysis
Sign in

Innate Pharma S.A. (IPHA)

Nasdaq: IPHA · Biological Products, (No Diagnostic Substances) · Marseille · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.3
◀ Past 5.9● Present 4.0▶ Future 3.5
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

94 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Innate Pharma S.A.’s names, not what it holds today.

Patents granted
94
94 utility, 1976 to Dec 31, 2025
Granted in 2025
6
Against 7 in 2024 and 6 in 2023
Applications published
182
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals20
Biotechnology10
Analysis of biological materials2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
INNATE PHARMA its own name
FR, as the owner printed on each patent
94 granted
59 published
INNATE PHARMA its own name
named as the applicant on its applications, in FR
0 granted
123 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 21, 202512,448,442Treatment of T cell lymphomaPharmaceuticalsINNATE PHARMA
Jul 22, 202512,365,731NKp46 binding agentsPharmaceuticalsINNATE PHARMA
Mar 18, 202512,252,543Multispecific NK engager proteinBiotechnologyINNATE PHARMA
Feb 18, 202512,227,569Humanized antibodies with increased stabilityPharmaceuticalsINNATE PHARMA
Jan 28, 202512,209,126Treatment of cancerPharmaceuticalsINNATE PHARMA
Jan 21, 202512,202,907Nucleic acids encoding and methods of producing proteins comprising antibody chainsAnalysis of biological materialsINNATE PHARMA
Sep 10, 202412,084,498Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaBiotechnologyINNATE PHARMA
Jul 16, 202412,037,392Treatment regimens using anti-NKG2A antibodiesPharmaceuticalsINNATE PHARMA
Jun 4, 202411,999,784Treatment of peripheral T cell lymphomaBiotechnologyINNATE PHARMA
Apr 30, 202411,970,535Treatment with anti-KIR3DL2 agentsPharmaceuticalsINNATE PHARMA
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 25, 20252025/0297004NECTIN-4 BINDING AGENTSPharmaceuticalsINNATE PHARMA
Jul 24, 20252025/0236678COMPOSITIONS AND METHODS FOR TREATING CANCERAnalysis of biological materialsINNATE PHARMA
Jul 17, 20252025/0230237HUMANIZED ANTIBODIES WITH INCREASED STABILITYPharmaceuticalsINNATE PHARMA
Jul 3, 20252025/0215107MULTISPECIFIC NK ENGAGER PROTEINPharmaceuticalsINNATE PHARMA
Jun 19, 20252025/0197528NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERINGBiotechnologyINNATE PHARMA
Mar 20, 20252025/0092130COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMABiotechnologyINNATE PHARMA
Jan 2, 20252025/0002601MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2BiotechnologyINNATE PHARMA
Dec 26, 20242024/0425586TREATMENT OF PERIPHERAL T CELL LYMPHOMABiotechnologyINNATE PHARMA
Nov 28, 20242024/0392008MULTISPECIFIC PROTEINS BINDING TO NKP46, A CYTOKINE RECEPTOR, A TUMOUR ANTIGEN AND CD16ABiotechnologyINNATE PHARMA
Nov 28, 20242024/0391999TREATMENT WITH ANTI-KIR3DL2 AGENTSPharmaceuticalsINNATE PHARMA
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Biotechnology 9 · Analysis of biological materials 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IPHA · research, not advice